Ann Liver Transplant.  2024 May;4(1):1-9. 10.52604/alt.24.0005.

How to prevent chronic kidney disease after liver transplantation?

• Lee JG

• KMID: 2560935
• DOI: http://doi.org/10.52604/alt.24.0005

Abstract

Risk factors contributing to chronic kidney disease (CKD) after liver transplantation (LT) are multifaceted, involving episodes of acute kidney injury (AKI), donor-related factors, and immunosuppressive medication, notably calcineurin inhibitors (CNIs). AKI is a common complication post-LT, affecting nearly half of all patients, with approximately 15% requiring kidney replacement therapy. Recipient factors such as metabolic syndrome, diabetes, obesity, age, ethnicity, hepatitis C infection, and prior malignancy contribute to post-transplant CKD. Maintenance immunosuppressive regimens, particularly early CNI administration, may exacerbate CKD progression by inducing chronic vasoconstriction of kidney arterioles. Early detection of risk factors, addressing modifiable ones, and minimizing perioperative AKI are essential focuses for high-risk individuals. Prioritizing strategies targeting CKD management, diabetes, and hypertension, along with the utilization of Kidney Disease Improving Global Outcomes (KDIGO) recommendations, is crucial for effective management. Blood pressure targets, pharmacological interventions, and timely referral to nephrologists for access creation are integral components of CKD management. Additionally, optimization of immunosuppressive protocols, primarily through CNI minimization or withdrawal, and considering alternative agents like mammalian target of rapamycin (mTOR) inhibitors or antimetabolites, play pivotal roles in preserving renal function. Adjusting the immunosuppressive regimen, particularly by minimizing CNIs in the first post-transplant year, can slow kidney dysfunction progression. Identifying and addressing risk factors for renal dysfunction, optimizing perioperative care, and tailoring immunosuppressive regimens are essential steps to enhance long-term outcomes following LT.

Keyword

Chronic kidney insufficiency; Immunosuppressants; Acute kidney injury; Liver transplantation; Long-term effect

Figure

• 

  Figure 1 Risk factors for chronic kidney disease following liver transplantation. MELD, model for end-stage liver disease.

Reference

1. Allen AM, Kim WR, Therneau TM, Larson JJ, Heimbach JK, Rule AD. 2014; Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate. J Hepatol. 61:286–292. DOI: 10.1016/j.jhep.2014.03.034. PMID: 24713190. PMCID: PMC4160310.

2. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. 2003; Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 349:931–940. DOI: 10.1056/NEJMoa021744. PMID: 12954741.

3. Kalisvaart M, Schlegel A, Trivedi PJ, Roberts K, Mirza DF, Perera T, et al. 2019; Chronic kidney disease after liver transplantation: impact of extended criteria grafts. Liver Transpl. 25:922–933. DOI: 10.1002/lt.25468. PMID: 30947384.

4. Schmitt TM, Kumer SC, Al-Osaimi A, Shah N, Argo CK, Berg C, et al. 2009; Combined liver-kidney and liver transplantation in patients with renal failure outcomes in the MELD era. Transpl Int. 22:876–883. DOI: 10.1111/j.1432-2277.2009.00887.x. PMID: 19413580.

5. Kim DG, Hwang S, Kim JM, Ryu JH, You YK, Choi D, et al. 2022; Non-renal risk factors for chronic kidney disease in liver recipients with functionally intact kidneys at 1 month. J Clin Med. 11:4203. DOI: 10.3390/jcm11144203. PMID: 35887972. PMCID: PMC9315935.

6. Lee J, Kim DG, Lee JY, Lee JG, Joo DJ, Kim SI, et al. 2019; Impact of model for end-stage liver disease score-based allocation system in Korea: a nationwide study. Transplantation. 103:2515–2522. DOI: 10.1097/TP.0000000000002755. PMID: 30985735.

7. Farouk SS, Rein JL. 2020; The many faces of calcineurin inhibitor toxicity-what the FK? Adv Chronic Kidney Dis. 27:56–66. DOI: 10.1053/j.ackd.2019.08.006. PMID: 32147003. PMCID: PMC7080294.

8. Israni AK, Xiong H, Liu J, Salkowski N, Trotter JF, Snyder JJ, et al. 2013; Predicting end-stage renal disease after liver transplant. Am J Transplant. 13:1782–1792. DOI: 10.1111/ajt.12257. PMID: 23668976.

9. O'Riordan A, Donaldson N, Cairns H, Wendon J, O'Grady JG, Heaton N, et al. 2010; Risk score predicting decline in renal function postliver transplant: role in patient selection for combined liver kidney transplantation. Transplantation. 89:1378–1384. DOI: 10.1097/TP.0b013e3181d9e195. PMID: 20463650.

10. Sharma P, Goodrich NP, Schaubel DE, Guidinger MK, Merion RM. 2013; Patient-specific prediction of ESRD after liver transplantation. J Am Soc Nephrol. 24:2045–2052. DOI: 10.1681/ASN.2013040436. PMID: 24029423. PMCID: PMC3839556.

11. Shaffi K, Uhlig K, Perrone RD, Ruthazer R, Rule A, Lieske JC, et al. 2014; Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis. 63:1007–1018. DOI: 10.1053/j.ajkd.2014.01.436. PMID: 24703720. PMCID: PMC4113340.

12. Allen AM, Kim WR, Larson JJ, Colby C, Therneau TM, Rule AD. 2015; Serum cystatin C as an indicator of renal function and mortality in liver transplant recipients. Transplantation. 99:1431–1435. DOI: 10.1097/TP.0000000000000552. PMID: 25654627. PMCID: PMC4551433.

13. Rodríguez-Perálvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. 2017; Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev. 3:CD011639. DOI: 10.1002/14651858.CD011639.pub2. PMID: 28362060. PMCID: PMC6464256.

14. Wagner D, Kniepeiss D, Stiegler P, Zitta S, Bradatsch A, Robatscher M, et al. 2012; The assessment of GFR after orthotopic liver transplantation using cystatin C and creatinine-based equations. Transpl Int. 25:527–536. DOI: 10.1111/j.1432-2277.2012.01449.x. PMID: 22369048.

15. Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. 2021; Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline. Ann Intern Med. 174:385–394. DOI: 10.7326/M20-5938. PMID: 33166222.

16. Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. 2013; Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 158:825–830. DOI: 10.7326/0003-4819-158-11-201306040-00007. PMID: 23732715.

17. Najeed SA, Saghir S, Hein B, Neff G, Shaheen M, Ijaz H, et al. 2011; Management of hypertension in liver transplant patients. Int J Cardiol. 152:4–6. DOI: 10.1016/j.ijcard.2010.12.021. PMID: 21215474.

18. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. 2020; KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 98(4S):S1–S115. DOI: 10.1016/j.kint.2020.06.019. PMID: 32998798.

19. Giri Ravindran S, Kakarla M, Ausaja Gambo M, Yousri Salama M, Haidar Ismail N, Tavalla P, et al. 2022; The effects of sodium-glucose cotransporter-2 inhibitors (SLGT-2i) on cardiovascular and renal outcomes in non-diabetic patients: a systematic review. Cureus. 14:e25476. DOI: 10.7759/cureus.25476. PMID: 35800782. PMCID: PMC9246463.

20. Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS, Abreo K, et al. 2020; KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 75(4 Suppl 2):S1–S164. Erratum in: Am J Kidney Dis 2021;77:551. DOI: 10.1053/j.ajkd.2019.12.001. PMID: 32778223.

21. Al Riyami D, Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M. 2008; Decreased survival in liver transplant patients requiring chronic dialysis: a Canadian experience. Transplantation. 85:1277–1280. DOI: 10.1097/TP.0b013e31816c4e6b. PMID: 18475183.

22. Yunhua T, Qiang Z, Lipeng J, Shanzhou H, Zebin Z, Fei J, et al. 2018; Liver transplant recipients with end-stage renal disease largely benefit from kidney transplantation. Transplant Proc. 50:202–210. DOI: 10.1016/j.transproceed.2017.11.009. PMID: 29407310.

23. Srinivas TR, Stephany BR, Budev M, Mason DP, Starling RC, Miller C, et al. 2010; An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation. Clin J Am Soc Nephrol. 5:1881–1886. DOI: 10.2215/CJN.02950410. PMID: 20813856. PMCID: PMC2974390.

24. Saiprasertkit N, Nihei CH, Bargman JM. 2018; Peritoneal dialysis in orthotopic liver transplantation recipients. Perit Dial Int. 38:44–48. DOI: 10.3747/pdi.2017.00134. PMID: 29162680.

25. Levitsky J, O'Leary JG, Asrani S, Sharma P, Fung J, Wiseman A, et al. 2016; Protecting the kidney in liver transplant recipients: practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 16:2532–2544. DOI: 10.1111/ajt.13765. PMID: 26932352. PMCID: PMC5007154.

26. Duvoux C, Pageaux GP. 2011; Immunosuppression in liver transplant recipients with renal impairment. J Hepatol. 54:1041–1054. DOI: 10.1016/j.jhep.2010.12.001. PMID: 21145927.

27. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. 2006; Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006:CD005161. DOI: 10.1002/14651858.CD005161. PMID: 17054241. PMCID: PMC8865611.

28. Toniutto P, Germani G, Ferrarese A, Bitetto D, Zanetto A, Fornasiere E, et al. 2022; An essential guide for managing post-liver transplant patients: what primary care physicians should know. Am J Med. 135:157–166. DOI: 10.1016/j.amjmed.2021.08.005. PMID: 34508700.

29. Dong V, Nadim MK, Karvellas CJ. 2021; Post-liver transplant acute kidney injury. Liver Transpl. 27:1653–1664. DOI: 10.1002/lt.26094. PMID: 33963666.

30. Lim SY, Wang R, Tan DJH, Ng CH, Lim WH, Quek J, et al. 2021; A meta-analysis of the cumulative incidence, risk factors, and clinical outcomes associated with chronic kidney disease after liver transplantation. Transpl Int. 34:2524–2533. DOI: 10.1111/tri.14149. PMID: 34714569.

31. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. 2006; Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc. 38:3633–3635. Erratum in: Transplant Proc 2007;39:779. DOI: 10.1016/j.transproceed.2006.10.110. PMID: 17175352.

32. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. 2005; Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl. 11:1064–1072. DOI: 10.1002/lt.20490. PMID: 16123958.

33. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. 2009; Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 9:327–336. DOI: 10.1111/j.1600-6143.2008.02493.x. PMID: 19120077.

34. Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, et al. 2010; Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation. 89:1504–1510. DOI: 10.1097/TP.0b013e3181db8cf0. PMID: 20495510.

35. Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. 2011; Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 24:640–650. DOI: 10.1111/j.1432-2277.2011.01250.x. PMID: 21429047.

36. Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, et al. 2004; Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 10:728–733. DOI: 10.1002/lt.20144. PMID: 15162466.

37. Di Maira T, Little EC, Berenguer M. Immunosuppression in liver transplant. Best Pract Res Clin Gastroenterol. 2020; 46-47:101681. DOI: 10.1016/j.bpg.2020.101681. PMID: 33158467.

38. Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, et al. 2005; The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl. 11:1258–1264. DOI: 10.1002/lt.20520. PMID: 16184544.

39. Lange NW, Salerno DM, Sammons CM, Jesudian AB, Verna EC, Brown RS Jr. 2018; Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. Clin Transplant. 32:e13415. DOI: 10.1111/ctr.13415. PMID: 30276862.

40. Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S, et al. 2014; Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 14:1817–1827. DOI: 10.1111/ajt.12810. PMID: 25041339. PMCID: PMC4140547.

41. Panackel C, Mathew JF, Fawas NM, Jacob M. 2022; Immunosuppressive drugs in liver transplant: an insight. J Clin Exp Hepatol. 12:1557–1571. DOI: 10.1016/j.jceh.2022.06.007. PMID: 36340316. PMCID: PMC9630030.

42. Boudjema K, Camus C, Saliba F, Calmus Y, Salamé E, Pageaux G, et al. 2011; Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant. 11:965–976. DOI: 10.1111/j.1600-6143.2011.03486.x. PMID: 21466650.

43. Trotter JF. 2003; Sirolimus in liver transplantation. Transplant Proc. 35(3 Suppl):193S–200S. DOI: 10.1016/S0041-1345(03)00234-3. PMID: 12742496.

44. Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, et al. 2013; Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 19:675–689. DOI: 10.1002/lt.23658. PMID: 23775875.

45. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, et al. 2006; Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 12:1640–1648. Erratum in: Liver Transpl 2006;12:1726. DOI: 10.1002/lt.20707. PMID: 16598777.

46. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, et al. 2013; Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 13:1734–1745. DOI: 10.1111/ajt.12280. PMID: 23714399.

47. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. 2014; Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 14:701–710. DOI: 10.1111/ajt.12615. PMID: 24502384. PMCID: PMC4285226.

48. Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, et al. 2010; Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 10:2252–2262. DOI: 10.1111/j.1600-6143.2010.03128.x. PMID: 20486905.

49. Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, et al. 2012; A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant. 12:1855–1865. DOI: 10.1111/j.1600-6143.2012.04049.x. PMID: 22494671.

50. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. 2005; Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation. 80:1198–1203. DOI: 10.1097/01.tp.0000185200.17589.74. PMID: 16314786.

51. Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB. 2006; Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant. 6:429–433. DOI: 10.1111/j.1600-6143.2005.01195.x. PMID: 16426332.

52. Letavernier E, Legendre C. 2008; mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando). 22:125–130. DOI: 10.1016/j.trre.2007.12.001. PMID: 18631865.

53. Arnau A, Ruiz JC, Rodrigo E, Quintanar JA, Arias M. 2011; Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors? Transplant Proc. 43:2194–2195. DOI: 10.1016/j.transproceed.2011.06.045. PMID: 21839231.

54. Nashan B, Schemmer P, Braun F, Schlitt HJ, Pascher A, Klein CG, et al. 2022; Early everolimus-facilitated reduced tacrolimus in liver transplantation: results from the randomized HEPHAISTOS trial. Liver Transpl. 28:998–1010. DOI: 10.1002/lt.26298. PMID: 34525259. PMCID: PMC9291476.

55. Cillo U, Saracino L, Vitale A, Bertacco A, Salizzoni M, Lupo F, et al. 2019; Very early introduction of everolimus in de novo liver transplantation: results of a multicenter, prospective, randomized trial. Liver Transpl. 25:242–251. DOI: 10.1002/lt.25400. PMID: 30592371.

56. Saliba F, Dharancy S, Salamé E, Conti F, Eyraud D, Radenne S, et al. 2020; Time to conversion to an everolimus-based regimen: renal outcomes in liver transplant recipients from the EVEROLIVER registry. Liver Transpl. 26:1465–1476. DOI: 10.1002/lt.25879. PMID: 32869469.

57. Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, et al. 2012; Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 12:694–705. DOI: 10.1111/j.1600-6143.2011.03919.x. PMID: 22233522.

58. Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J, et al. 2006; Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl. 12:1755–1760. DOI: 10.1002/lt.20903. PMID: 17133564.

59. Goralczyk AD, Bari N, Abu-Ajaj W, Lorf T, Ramadori G, Friede T, et al. 2012; Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials. Am J Transplant. 12:2601–2607. DOI: 10.1111/j.1600-6143.2012.04157.x. PMID: 22813081.